Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amitiza

- PMLiVE

Generic for Lilly’s Evista in US ‘within a month’

Teva to launch copy of osteoporosis drug

- PMLiVE

NICE relents and backs Pfizer’s Inlyta

Recommends drug to treat advanced kidney cancer on NHS in England

- PMLiVE

NHS promotes better drug understanding

‘My Medicines, My Health’ kicks off in north east England

- PMLiVE

Compulsory evaluation in France

French authorities will expect robust health economic cases to be made for some drugs

National Institute for Health and Care Excellence NICE logo

NICE: Alexion must justify Soliris’ high cost

UK body unable to recommend ‘ultra-orphan’ drug

Canbex hires former Lilly medical director

Alberto Lledó joins UK-based biotech

- PMLiVE

NICE set to reject Lilly’s Alimta for new use in lung cancer

Drug deemed not cost-effective use of NHS resources in new indication

- PMLiVE

NICE relents and gives Pixuvri limited backing

Recommends Cell Therapeutics drug for an aggressive form of cancer

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

- PMLiVE

Value-based assessment

NICE is set to modify the way it operates, but the changes shouldn’t come as a surprise

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links